EE658 Budget Impact Analysis for Multi-Indication Targeted Therapy: A Case Study of Cabozantinib Cost-Saving in Algeria as Treatment Option in First-Line Second-Line Renal-Cell Carcinoma and Second-Line Hepatocellular Carcinoma
Abstract
Authors
M Belouizdad K Guesmi N Oulmane N Kezzal N Abed S Stamboul N Touafek